Nonpeptidic, tricyclic FTase inhibitors.

FTase inhibitor SCH44342 had no in vivo efficacy. Further substitutions led to SCH66336, a highly potent FTase inhibitor, which was found to have therapeutically useful serum levels and half-lives when given orally to rodents and primates. SCH66336 is being tested in human clinical phase II trials.